Heart failure commonly results from ischemic or hypertensive disease, and novel strategies are sorely needed to address the ever-expanding population of patients with heart failure world-wide. Over the past two years we have explored the role of a novel cardiac-specific protein kinase, troponin I type 3 interacting kinase (gene name TNNI3K) in regulating ischemic injury, post-MI remodeling, and pressure overload-induced remodeling. We have employed a number of strategies including 1) transgenic mice expressing either wild-type, constitutively active, or kinase-inactive TNNI3K, 2) conditional cardiac-specific deletion of TNNI3K (CKO mice), and 3) novel small molecule inhibitors of TNNI3K generated by our collaborators at Glaxo-Smith-Kline that are able to be used both in vitro and in vivo. All of our data support two key conclusions: 1) Inhibition of TNNI3K is strongly protective, and activation of TNNI3K is highly detrimental, in the setting of ischemia/reperfusion (I/R) injury, and 2) TNNI3K appears to be a central regulator of fibrotic remodeling in the heart. We now propose to determine the molecular mechanisms by which TNNI3K regulates these processes, thereby expanding our understanding of mechanisms of ischemic injury and repair. In our Specific Aims we propose to identify TNNI3K targets from genomic analyses and have already identified a profound role of TNNI3K in regulating expression of genes implicated in fibrotic remodeling. This is consistent with the significant reduction in fibrosis we observe in mice subjected to thoracic aortic constriction that were treated with one of the small molecule inhibitors. We will also employ proteomic approaches to identify direct substrates of TNNI3K using the analog sensitive kinase allele (ASKA) approach pioneered by Shokat and co-workers. Finally, we will focus on the role of select substrates identified in Aim 2, and will determine ther role in ischemic injury and post-infarct remodeling. Given our successful use of small molecule inhibitors targeting TNNI3K in vivo, and the demonstrated safety of this approach in our pre-clinical models, we believe that the stage could be set for fairly rapid translation to clinical trals if our hypotheses are borne out.

Public Health Relevance

We have identified a novel critical role of TNNI3K, a cardiac-specific protein kinase of poorly understood function, in regulating the response to ischemic injury and fibrotic remodeling in the heart. Herein we will identify mechanisms of these effects.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Adhikari, Bishow B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Zhou, Jibin; Ahmad, Firdos; Parikh, Shan et al. (2016) Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy. Circ Res 118:1208-22
Lal, Hind; Ahmad, Firdos; Woodgett, James et al. (2015) The GSK-3 family as therapeutic target for myocardial diseases. Circ Res 116:138-49
Springer, Jochen; Tschirner, Anika; Haghikia, Arash et al. (2014) Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J 35:932-41
Lal, Hind; Ahmad, Firdos; Parikh, Shan et al. (2014) Troponin I-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease. Circ J 78:1514-9
Lal, Hind; Ahmad, Firdos; Zhou, Jibin et al. (2014) Cardiac fibroblast glycogen synthase kinase-3? regulates ventricular remodeling and dysfunction in ischemic heart. Circulation 130:419-30
Ahmad, Firdos; Lal, Hind; Zhou, Jibin et al. (2014) Cardiomyocyte-specific deletion of Gsk3? mitigates post-myocardial infarction remodeling, contractile dysfunction, and heart failure. J Am Coll Cardiol 64:696-706
Force, Thomas; Wang, Yibin (2013) Mechanism-based engineering against anthracycline cardiotoxicity. Circulation 128:98-100
Zhou, Jibin; Freeman, Theresa A; Ahmad, Firdos et al. (2013) GSK-3? is a central regulator of age-related pathologies in mice. J Clin Invest 123:1821-32
Ky, Bonnie; Vejpongsa, Pimprapa; Yeh, Edward T H et al. (2013) Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res 113:754-64
Vagnozzi, Ronald J; Gatto Jr, Gregory J; Kallander, Lara S et al. (2013) Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart. Sci Transl Med 5:207ra141

Showing the most recent 10 out of 13 publications